321 related articles for article (PubMed ID: 30387804)
1. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.
Rogers-Broadway KR; Kumar J; Sisu C; Wander G; Mazey E; Jeyaneethi J; Pados G; Tsolakidis D; Klonos E; Grunt T; Hall M; Chatterjee J; Karteris E
Int J Mol Med; 2019 Jan; 43(1):47-56. PubMed ID: 30387804
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.
Rogers-Broadway KR; Chudasama D; Pados G; Tsolakidis D; Goumenou A; Hall M; Karteris E
Int J Oncol; 2016 Jul; 49(1):133-43. PubMed ID: 27211906
[TBL] [Abstract][Full Text] [Related]
3. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
5. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
6. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.
Das F; Bera A; Ghosh-Choudhury N; Abboud HE; Kasinath BS; Choudhury GG
PLoS One; 2014; 9(10):e109608. PubMed ID: 25333702
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
8. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
9. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
Yoon MS
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
[TBL] [Abstract][Full Text] [Related]
10. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
11. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
13. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
14. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.
Cuesta R; Gritsenko MA; Petyuk VA; Shukla AK; Tsai CF; Liu T; McDermott JE; Holz MK
Mol Cell Proteomics; 2019 Aug; 18(8):1607-1618. PubMed ID: 31189691
[TBL] [Abstract][Full Text] [Related]
15. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 and mTORC2 play different roles in regulating cardiomyocyte differentiation from embryonic stem cells.
Zheng B; Wang J; Tang L; Shi J; Zhu D
Int J Dev Biol; 2017; 61(1-2):65-72. PubMed ID: 28287249
[TBL] [Abstract][Full Text] [Related]
17. mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation.
Ding X; Bloch W; Iden S; Rüegg MA; Hall MN; Leptin M; Partridge L; Eming SA
Nat Commun; 2016 Oct; 7():13226. PubMed ID: 27807348
[TBL] [Abstract][Full Text] [Related]
18. microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.
Maity S; Bera A; Ghosh-Choudhury N; Das F; Kasinath BS; Choudhury GG
Exp Cell Res; 2018 Mar; 364(1):5-15. PubMed ID: 29397070
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxyvitamin D
Kim Y; Kim HS; Sohn J; Ji JD
Biochem Biophys Res Commun; 2019 Nov; 519(4):909-915. PubMed ID: 31563324
[TBL] [Abstract][Full Text] [Related]
20. mTOR in Lung Neoplasms.
Krencz I; Sebestyen A; Khoor A
Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
